AI Insight
The NRG-HN009 trial compared two cisplatin dosing schedules for treating locally advanced head and neck cancer in combination with radiation therapy: a higher dose administered every three weeks versus a lower dose given weekly. The study specifically examined outcomes in p16-negative head and neck cancer patients, finding that the weekly low-dose regimen did not demonstrate fewer serious side effects compared to the three-week high-dose schedule. This randomized trial provided the first substantial evidence comparing these two commonly used treatment approaches in clinical practice.
Why it matters
This research helps oncologists make evidence-based decisions about which cisplatin regimen to use when treating head and neck cancer patients, as both schedules are currently employed despite previously lacking direct comparative data. The findings suggest that the choice between dosing schedules should be based on factors other than reduction of serious side effects, since weekly dosing does not offer this anticipated advantage.
Understand the Science
Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer. However, before NRG-HN009, there was limited randomized evidence to determine which regimen provided the best balance of cancer control and treatment-related side effects.
Source: Weekly cisplatin fails to show fewer serious side effects in p16-negative head and neck cancer